DUB targets explored
In the DUB field
Commercializing expert research into
Dubs and Ubiquitin pathway
Mission Therapeutics’ strategy is to create value by advancing its pipeline programs through early clinical development, and preferentially with a patient selection strategy to enhance the probability of demonstrating early signs of efficacy. Selected programmes may be advanced in partnership with other pharmaceutical companies.
- Mission Therapeutics’ Collaboration with AbbVie Nominated for Scrip Best Partnership Alliance Award16th September 2019
- Dr. James Summers Appointed to Mission Therapeutics’ Board of Directors1st May 2019
- Mission Therapeutics to Present at the Cowen and Company 39th Annual Healthcare Conference6th March 2019